Current filters:

Forest Laboratories

1 to 9 of 405 results

FDA accepts Actavis NDA for eluxadoline

FDA accepts Actavis NDA for eluxadoline


Ireland-headquartered generic drug major Actavis says that the US Food and Drug Administration has accepted…

ActaviseluxadolineForest LaboratoriesFuriex PharmaceuticalsGastro-intestinalsPharmaceuticalRegulationUSA

Actavis and Forest to divest four generics to gain FTC OK for merger


In order for Ireland-headquartered generics major Actavis to complete its previously-announced $25 billion…

ActavisForest LaboratoriesGeneric pharmaceuticalsGenericsHealth Medical PharmaMedicinePharmaceutical industryPharmacologyRegulationUSA

Positive Ph III results with Forest Labs’ vilazodone in GAD


US drugmaker Forest Laboratories has released positive top-line results from three Phase III trials evaluating…

Forest LaboratoriesNeurologicalPharmaceuticalResearchvilazodone

Forest appeases shareholders over Actavis deal


US drugmaker Forest Laboratories has reached a settlement with shareholders over its deal with generics…

ActavisBusinessBusiness FinanceEnvironmentForest LaboratoriesMajorMergers & AcquisitionsNew York Stock ExchangePharmaceuticalUSA

Adamas Pharma gets $25 million milestone from Forest Labs


Adamas Pharmaceuticals says it has received a $25 million milestone payment from Forest Laboratories…

Adamas PharmaceuticalsFinancialForest LaboratoriesMDX-8704NeurologicalPharmaceuticalRegulationUSA

Actavis announces proposed Senior Leadership Team

Actavis announces proposed Senior Leadership Team


US generics major Actavis (NYSE: ACT) has announced the proposed senior management team that will lead…

ActavisBiosimilarsBoardroomForest LaboratoriesPharmaceuticalUSA

Forest Labs sales top analysts’ forecasts


US drugmaker Forest Laboratories, currently the subject of a takeover by Actavis, has reported diluted…

FinancialForest LaboratoriesPharmaceutical

1 to 9 of 405 results

Back to top